Physician profile
Ioana Fat
NPI 1205082724
$6,105.29
in general payments reported to CMS, 2019-2025
44 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $32.82 · 2021: $14.62 · 2022: $127 · 2023: $1,401 · 2024: $2,287 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,808.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $649.12 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.22 | 2019-2025 | Jardiance |
| Amgen INC. | $521.22 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $439.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $410.30 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $402.57 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $397.79 | 2019-2025 | |
| Insulet Corporation | $309.98 | 2024-2025 | Omnipod |
| Tolmar, INC. | $278.73 | 2023-2025 | Jatenzo |
| Mannkind Corporation | $238.30 | 2022-2025 | Afrezza |
| Antares Pharma, INC. | $218.37 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $152.90 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $147.43 | 2020-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $129.49 | 2023-2025 | |
| Medtronic, INC. | $118.51 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $91.12 | 2024-2025 | Nexletol |
| Pfizer INC. | $72.62 | 2024 | |
| Ascendis Pharma Endocrinology INC | $66.26 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $63.83 | 2023-2025 | Strensiq, Ultomiris |
| Ardelyx, INC. | $63.29 | 2024 | Ibsrela |
| Cequr Corporation | $62.18 | 2024-2025 | Cequr Simplicity |
| Vifor Pharma, INC. | $48.83 | 2023 | Veltassa |
| Corcept Therapeutics | $45.86 | 2025 | Korlym |
| Halozyme INC | $45.46 | 2023 | |
| Novartis Pharmaceuticals Corporation | $44.90 | 2024 | |
| Kyowa Kirin, INC. | $43.38 | 2024 | Crysvita |
| Exact Sciences Corporation | $42.54 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $41.89 | 2025 | Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $40.67 | 2023 | |
| Nevro Corp. | $34.78 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $32.99 | 2019-2020 | |
| Sequel Med Tech, LLC | $25.83 | 2025 | Twiist |
| Alnylam Pharmaceuticals INC. | $25.60 | 2024 | Onpattro |
| Medtronic Minimed, INC. | $23.52 | 2019 | |
| Calliditas Therapeutics US INC. | $22.36 | 2024 | |
| Ionis Pharmaceuticals, INC. | $21.59 | 2025 | Tryngolza |
| Genzyme Corporation | $20.60 | 2024 | |
| Neurocrine Biosciences, INC. | $20.00 | 2025 | |
| Averitas Pharma INC. | $19.50 | 2023 | Qutenza |
| Tandem Diabetes Care, INC. | $18.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shield Therapeutics INC | $18.04 | 2024 | |
| Ani Pharmaceuticals, INC. | $17.44 | 2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $13.55 | 2023 | Jynarque |
| Abbott Laboratories | $13.17 | 2024 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioana Fat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.